A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD
- PMID: 31303266
- PMCID: PMC6689324
- DOI: 10.1016/j.euroneuro.2019.06.006
A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD
Abstract
A large proportion of schizophrenia patients treated with second generation antipsychotics will develop Obsessive Compulsive Disorder (OCD). However, there are few studies about the impact of this comorbidity and who is at higher risk. In this study of clozapine-treated patients, we aimed to determine the impact on outcome of clozapine-induced OCD, as well as the clinical and sociodemographic risk factors related to OCD-onset in clozapine patients. We had strict and novel inclusion criteria to minimise mis-identification of cases. The Obsessive-Compulsive Inventory-Revised (OCI-R) was used to divide 231 clozapine-treated patients into extreme cases of OCD (OCI ≥ 24 or checking subscale ≥6) versus non-OCD (OCI <15 and checking subscale <4). The Global Assessment of Functioning (GAF), short version of Warwick-Edinburgh Wellbeing scale and Clinical Global Impression for schizophrenia (CGI) scales were used to determine outcome. Socio-demographic information was used to identify the risk factors for OCD development. We found that schizophrenia patients with OCD symptoms had a significantly lower patient rated wellbeing scores (p < 0.001) only (no difference in clinician rated wellbeing scores), higher CGI positive (p < 0.01) and higher CGI depressive scores (p < 0.05). The only risk factors that reached significance level were higher treatment dose (p < 0.01) and younger paternal age at birth (p < 0.05). There is scope for future studies based on e.g. imaging and genetic studies to further investigate causality, and in improving clinician screening for OCD.
Keywords: Antipsychotic; Clozapine; Obsessive compulsive disorder; Schizophrenia.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Figures

References
-
- Baytunca B., Kalyoncu T., Ozel I., Erermiş S., Kayahan B., Öngur D. Early onset schizophrenia associated with obsessive-compulsive disorder: clinical features and correlates. Clin. Neuropharmacol. 2017;40:243–245. - PubMed
-
- Brander G., Rydell M., Kuja-Halkola R., Fernández de la Cruz L., Lichtenstein P., Serlachius E., Rück C., Almqvist C., D'Onofrio B.M., Larsson H., Mataix-Cols D. Association of perinatal risk factors with obsessive-compulsive disorder: a population-based birth cohort, sibling control study. JAMA Psychiatry. 2016;73:1135–1144. - PubMed
-
- Brown J.E., Mezquida G., Fernandez-Egea E. Well-being in clozapine-treated schizophrenia patients: the significance of positive symptoms. Compr. Psychiatry. 2016;68:140–146. - PubMed
-
- Chudal R., Leivonen S., Rintala H., Hinkka-Yli-Salomäki S., Sourander A. Parental age and the risk of obsessive compulsive disorder and Tourette syndrome / chronic tic disorder in a nationwide population-based sample. J. Affect. Disord. 2017;223:101–105. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical